<!DOCTYPE html>
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<title>Summary | Live FDCR Systematic Review</title>
<meta name="author" content="Mohsen Ebrahimi">
<meta name="description" content="Four major steps in the validation of fMRI drug cue reactivity (FDCR)-derived biomarkers  Four major steps in the validation of fMRI drug cue reactivity (FDCR)-derived biomarkers. After an...">
<meta name="generator" content="bookdown 0.34 with bs4_book()">
<meta property="og:title" content="Summary | Live FDCR Systematic Review">
<meta property="og:type" content="book">
<meta property="og:url" content="https://mohsenebrahimyir.github.io/fdcr/summary.html">
<meta property="og:description" content="Four major steps in the validation of fMRI drug cue reactivity (FDCR)-derived biomarkers  Four major steps in the validation of fMRI drug cue reactivity (FDCR)-derived biomarkers. After an...">
<meta name="twitter:card" content="summary">
<meta name="twitter:title" content="Summary | Live FDCR Systematic Review">
<meta name="twitter:description" content="Four major steps in the validation of fMRI drug cue reactivity (FDCR)-derived biomarkers  Four major steps in the validation of fMRI drug cue reactivity (FDCR)-derived biomarkers. After an...">
<!-- JS --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://kit.fontawesome.com/6ecbd6c532.js" crossorigin="anonymous"></script><script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="libs/bootstrap-4.6.0/bootstrap.min.css" rel="stylesheet">
<script src="libs/bootstrap-4.6.0/bootstrap.bundle.min.js"></script><link href="libs/Roboto-0.4.7/font.css" rel="stylesheet">
<script src="libs/bs3compat-0.5.0/transition.js"></script><script src="libs/bs3compat-0.5.0/tabs.js"></script><script src="libs/bs3compat-0.5.0/bs3compat.js"></script><link href="libs/bs4_book-1.0.0/bs4_book.css" rel="stylesheet">
<script src="libs/bs4_book-1.0.0/bs4_book.js"></script><link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Roboto:wght@300&amp;display=swap" rel="stylesheet">
<script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- CSS --><style type="text/css">
    
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  </style>
<link rel="stylesheet" href="stl/style.css">
</head>
<body data-spy="scroll" data-target="#toc">

<div class="container-fluid">
<div class="row">
  <header class="col-sm-12 col-lg-3 sidebar sidebar-book"><a class="sr-only sr-only-focusable" href="#content">Skip to main content</a>

    <div class="d-flex align-items-start justify-content-between">
      <h1>
        <a href="index.html" title="">Live FDCR Systematic Review</a>
      </h1>
      <button class="btn btn-outline-primary d-lg-none ml-2 mt-1" type="button" data-toggle="collapse" data-target="#main-nav" aria-expanded="true" aria-controls="main-nav"><i class="fas fa-bars"></i><span class="sr-only">Show table of contents</span></button>
    </div>

    <div id="main-nav" class="collapse-lg">
      <form role="search">
        <input id="search" class="form-control" type="search" placeholder="Search" aria-label="Search">
</form>

      <nav aria-label="Table of contents"><h2></h2>
        <ul class="book-toc list-unstyled">
<li><a class="" href="index.html">Live Systematic Review: Functional Magnetic Resonance Imaging Studies Drug Cue-Reactivity (FDCR) Studies in Addiction Medicine</a></li>
<li><a class="active" href="summary.html">Summary</a></li>
</ul>

        <div class="book-extra">
          
        </div>
      </nav>
</div>
  </header><main class="col-sm-12 col-md-9 col-lg-7" id="content"><div id="summary" class="section level1 unnumbered">
<h1>Summary<a class="anchor" aria-label="anchor" href="#summary"><i class="fas fa-link"></i></a>
</h1>
<div id="four-major-steps-in-the-validation-of-fmri-drug-cue-reactivity-fdcr-derived-biomarkers" class="section level2 unnumbered">
<h2>Four major steps in the validation of fMRI drug cue reactivity (FDCR)-derived biomarkers<a class="anchor" aria-label="anchor" href="#four-major-steps-in-the-validation-of-fmri-drug-cue-reactivity-fdcr-derived-biomarkers"><i class="fas fa-link"></i></a>
</h2>
<div class="float">
<img src="fig/Figure%201.png" style="width:95.0%" alt="Four major steps in the validation of fMRI drug cue reactivity (FDCR)-derived biomarkers. After an FDCR-derived biomarker is precisely specified, the biomarker’s context of use should be decided. After the analytical and clinical validation of the biomarker and cost-benefit analysis, the compiled evidence is presented for regulatory approval. The FDA evaluates the use of biomarkers for drug development through a biomarker qualification process involving the submission of a Letter of Intent, a Qualification Plan, and a Full Qualification Package, while use of FDCR-derived biomarker in preclinical or clinical contexts requires the endorsement of a constellation of other institutions"><div class="figcaption">
<strong>Four major steps in the validation of fMRI drug cue reactivity (FDCR)-derived biomarkers.</strong> After an FDCR-derived biomarker is precisely specified, the biomarker’s context of use should be decided. After the analytical and clinical validation of the biomarker and cost-benefit analysis, the compiled evidence is presented for regulatory approval. The FDA evaluates the use of biomarkers for drug development through a biomarker qualification process involving the submission of a Letter of Intent, a Qualification Plan, and a Full Qualification Package, while use of FDCR-derived biomarker in preclinical or clinical contexts requires the endorsement of a constellation of other institutions</div>
</div>
</div>
<div id="global-contribution-to-fmri-cue-reactivity-studies" class="section level2 unnumbered">
<h2>Global contribution to fMRI cue-reactivity studies<a class="anchor" aria-label="anchor" href="#global-contribution-to-fmri-cue-reactivity-studies"><i class="fas fa-link"></i></a>
</h2>
<div class="float">
<img src="fig/country.png" style="width:95.0%" alt="Global contribution to fMRI cue-reactivity studies. Number of fMRI cue-reactivity studies in each country, broken down by the type of addictive substance/ behavior. “Multiple” stands for those studies that included more than one type of addictive substance/ behavior."><div class="figcaption">
<strong>Global contribution to fMRI cue-reactivity studies.</strong>
Number of fMRI cue-reactivity studies in each country, broken down by the type of addictive substance/ behavior. “Multiple” stands for those studies that included more than one type of addictive substance/ behavior.</div>
</div>
</div>
<div id="fmri-cue-reactivity-studies-across-years" class="section level2 unnumbered">
<h2>fMRI cue-reactivity studies across years<a class="anchor" aria-label="anchor" href="#fmri-cue-reactivity-studies-across-years"><i class="fas fa-link"></i></a>
</h2>
<div class="float">
<img src="fig/Figure%202.png" style="width:95.0%" alt="fMRI cue-reactivity studies across years. Number of fMRI cue-reactivity studies each year from 1998 till the end of 2023, broken down by the type of addictive substance/ behavior. “Multiple” stands for those studies that included more than one type of addictive substance/ behavior."><div class="figcaption">
<strong>fMRI cue-reactivity studies across years.</strong>
Number of fMRI cue-reactivity studies each year from 1998 till the end of 2023, broken down by the type of addictive substance/ behavior. “Multiple” stands for those studies that included more than one type of addictive substance/ behavior.</div>
</div>
</div>
<div id="task-and-study-design-features-of-fmri-drug-cue-reactivity-studies" class="section level2 unnumbered">
<h2>Task and study design features of fMRI drug cue reactivity studies<a class="anchor" aria-label="anchor" href="#task-and-study-design-features-of-fmri-drug-cue-reactivity-studies"><i class="fas fa-link"></i></a>
</h2>
<div class="float">
<img src="fig/Figure%203.png" style="width:95.0%" alt="Task and study design features of fMRI drug cue reactivity studies. a. Number of time points in FDCR studies. Seventy-four studies scanned participants at two time points and five at three time points. b. Boxplot representing the distribution of median inter-scan intervals (in days), for FDCR studies with more than one scanning session. Eleven studies scanned individuals within the same day (interval = 0 days). c. Main FDCR task design type. d. Boxplot of the distribution of FDCR task durations. e. FDCR studies broken down by stimulus and substance/ behavior type. f. Paradigms combined with FDCR tasks in 44 studies in the database."><div class="figcaption">
<strong>Task and study design features of fMRI drug cue reactivity studies.</strong> a. Number of time points in FDCR studies. Seventy-four studies scanned participants at two time points and five at three time points. b. Boxplot representing the distribution of median inter-scan intervals (in days), for FDCR studies with more than one scanning session. Eleven studies scanned individuals within the same day (interval = 0 days). c. Main FDCR task design type. d. Boxplot of the distribution of FDCR task durations. e. FDCR studies broken down by stimulus and substance/ behavior type. f. Paradigms combined with FDCR tasks in 44 studies in the database.</div>
</div>
</div>
<div id="participants-in-fdcr-studies" class="section level2 unnumbered">
<h2>Participants in FDCR studies<a class="anchor" aria-label="anchor" href="#participants-in-fdcr-studies"><i class="fas fa-link"></i></a>
</h2>
<div class="float">
<img src="fig/Figure%204.png" style="width:95.0%" alt="Participants in FDCR studies. The Sankey diagram represents the number of participants in FDCR studies across study years, gender, population type, potentially addictive drugs and behaviors, and interventions."><div class="figcaption">
<strong>Participants in FDCR studies.</strong> The Sankey diagram represents the number of participants in FDCR studies across study years, gender, population type, potentially addictive drugs and behaviors, and interventions.</div>
</div>
</div>
<div id="biomarkers-in-fdcr-studies" class="section level2 unnumbered">
<h2>Biomarkers in FDCR studies<a class="anchor" aria-label="anchor" href="#biomarkers-in-fdcr-studies"><i class="fas fa-link"></i></a>
</h2>
<div class="float">
<img src="fig/Figure%205.png" style="width:95.0%" alt="Biomarkers in FDCR studies. a. fMRI cue-reactivity studies which can lead to the development of a biomarker, broken down by substance or behavior of interest in each study. Note that numbers do not sum to 357 and percentages do not sum to 100 since some studies fit no biomarker framework, for example cross-sectional studies with a single group of participants or those that include only non-clinical populations without follow-up, while some studies fit multiple categories. b. Dumbbell plot showing the number of significant and non-significant biomarker-related tests."><div class="figcaption">
<strong>Biomarkers in FDCR studies.</strong> a. fMRI cue-reactivity studies which can lead to the development of a biomarker, broken down by substance or behavior of interest in each study. Note that numbers do not sum to 357 and percentages do not sum to 100 since some studies fit no biomarker framework, for example cross-sectional studies with a single group of participants or those that include only non-clinical populations without follow-up, while some studies fit multiple categories. b. Dumbbell plot showing the number of significant and non-significant biomarker-related tests.</div>
</div>

</div>
</div>
  <div class="chapter-nav">
<div class="prev"><a href="index.html">Live Systematic Review: Functional Magnetic Resonance Imaging Studies Drug Cue-Reactivity (FDCR) Studies in Addiction Medicine</a></div>
<div class="empty"></div>
</div></main><div class="col-md-3 col-lg-2 d-none d-md-block sidebar sidebar-chapter">
    <nav id="toc" data-toggle="toc" aria-label="On this page"><h2></h2>
      <ul class="nav navbar-nav">
<li><a class="nav-link" href="#summary">Summary</a></li>
<li><a class="nav-link" href="#four-major-steps-in-the-validation-of-fmri-drug-cue-reactivity-fdcr-derived-biomarkers">Four major steps in the validation of fMRI drug cue reactivity (FDCR)-derived biomarkers</a></li>
<li><a class="nav-link" href="#global-contribution-to-fmri-cue-reactivity-studies">Global contribution to fMRI cue-reactivity studies</a></li>
<li><a class="nav-link" href="#fmri-cue-reactivity-studies-across-years">fMRI cue-reactivity studies across years</a></li>
<li><a class="nav-link" href="#task-and-study-design-features-of-fmri-drug-cue-reactivity-studies">Task and study design features of fMRI drug cue reactivity studies</a></li>
<li><a class="nav-link" href="#participants-in-fdcr-studies">Participants in FDCR studies</a></li>
<li><a class="nav-link" href="#biomarkers-in-fdcr-studies">Biomarkers in FDCR studies</a></li>
</ul>

      <div class="book-extra">
        <ul class="list-unstyled">
          
        </ul>
</div>
    </nav>
</div>

</div>
</div> <!-- .container -->

<footer class="bg-primary text-light mt-5"><div class="container"><div class="row">

  <div class="col-12 col-md-6 mt-3">
    <p>"<strong>Live FDCR Systematic Review</strong>", update date: <strong>2023-01-08</strong></p>
  </div>

  <div class="col-12 col-md-6 mt-3" style="display:none;">
    <p>This page was written by Mohsen Ebrahimi </p>
  </div>

</div></div>
</footer>
</body>
</html>
